Xiaolin Wang - Mar 1, 2023 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
EVP, Clinical Development
Signature
/s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang
Stock symbol
RVMD
Transactions as of
Mar 1, 2023
Transactions value $
$0
Form type
4
Date filed
3/3/2023, 03:17 PM
Previous filing
Dec 21, 2022
Next filing
Mar 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Award $0 +29K +95% $0.00 59.5K Mar 1, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Award $0 +102K $0.00 102K Mar 1, 2023 Common Stock 102K $26.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 51,550 restricted stock units.
F2 One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

EVP, Clinical Development